tetano
Editor, Senior Moderator
Virus Res. 2017 Apr 6. pii: S0168-1702(16)30814-0. doi: 10.1016/j.virusres.2017.04.002. [Epub ahead of print]
[h=1]Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome.[/h] Izzard L[SUP]1[/SUP], Dlugolenski D[SUP]1[/SUP], Xia Y[SUP]1[/SUP], McMahon M[SUP]1[/SUP], Middleton D[SUP]2[/SUP], Tripp RA[SUP]3[/SUP], Stambas J[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A vaccine efficacy in the elderly is generally poor and so identification of novel molecular adjuvants to improve immunogenicity is important to reduce the overall burden of disease. Short non-coding RNAs, known as microRNAs (miRNAs) are known to regulate gene expression and have the potential to influence immune responses. One such miRNA, miR-155, has been shown to modulate T and B cell development and function. We incorporated miR-155 into the influenza A virus (IAV) genome creating a self-adjuvanting 'live vaccine' with the ability to modify immunogenicity. Infection of mice with a recombinant influenza virus encoding miR-155 in the NS gene segment altered epitope-specific expansion of influenza-specific CD8[SUP]+[/SUP] T cells and induced significantly higher levels of neutralizing antibody.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] B cell; Influenza A; RNAi; T cell; Vaccine; miR-155
PMID: 28392443 DOI: 10.1016/j.virusres.2017.04.002
[h=1]Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome.[/h] Izzard L[SUP]1[/SUP], Dlugolenski D[SUP]1[/SUP], Xia Y[SUP]1[/SUP], McMahon M[SUP]1[/SUP], Middleton D[SUP]2[/SUP], Tripp RA[SUP]3[/SUP], Stambas J[SUP]4[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza A vaccine efficacy in the elderly is generally poor and so identification of novel molecular adjuvants to improve immunogenicity is important to reduce the overall burden of disease. Short non-coding RNAs, known as microRNAs (miRNAs) are known to regulate gene expression and have the potential to influence immune responses. One such miRNA, miR-155, has been shown to modulate T and B cell development and function. We incorporated miR-155 into the influenza A virus (IAV) genome creating a self-adjuvanting 'live vaccine' with the ability to modify immunogenicity. Infection of mice with a recombinant influenza virus encoding miR-155 in the NS gene segment altered epitope-specific expansion of influenza-specific CD8[SUP]+[/SUP] T cells and induced significantly higher levels of neutralizing antibody.
Copyright ? 2017. Published by Elsevier B.V.
[h=4]KEYWORDS:[/h] B cell; Influenza A; RNAi; T cell; Vaccine; miR-155
PMID: 28392443 DOI: 10.1016/j.virusres.2017.04.002